Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
20 Septiembre 2021 - 5:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, ocular surface diseases and
retinal diseases today announced the appointment Erik Pacyniak,
Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White,
Ph.D., D.A.B.T., Aerie’s Vice President of Research and Discovery.
Dr. Pacyniak will oversee all aspects of nonclinical toxicology and
drug disposition for Aerie. He most recently held a related
nonclinical safety assessment position at Mycovia Pharmaceuticals,
Inc.
In connection with his acceptance of the position as Director,
Toxicology, Dr. Pacyniak will receive awards totaling 16,900 stock
options that will vest over 4 years, with 25% vesting on the first
anniversary of the hire date and the remainder vesting ratably on
each of the subsequent 36 monthly anniversaries of the hire date.
This award was made outside of Aerie’s stockholder-approved equity
incentive plan and was approved by the Company’s independent
directors as an inducement material to Dr. Pacyniak entering into
employment with the Company in reliance on Nasdaq Listing Rule
5635(c)(4), which requires this public announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
ocular surface diseases and retinal diseases. Aerie’s first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated IOP in patients with open-angle glaucoma or ocular
hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic
solution) 0.02%/0.005%, the first and only fixed-dose combination
of Rhopressa® and the widely-prescribed PGA (prostaglandin analog)
latanoprost, was launched in the United States in May 2019. In
clinical trials of Rocklatan®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rocklatan®, including the product label, is available at
www.rocklatan.com. Aerie continues to focus on global expansion and
the development of additional product candidates and technologies
in ophthalmology, including for the treatment of dry eye disease,
wet age-related macular degeneration and diabetic macular edema.
More information is available at www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements in this press release include statements
regarding our intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: our
expectations regarding our ability to attract and retain executive
talent, the ability of such executive talent to adequately
discharge their responsibilities, the commercialization and
manufacturing of, as applicable, Rhopressa®, Rocklatan®,
Rhokiinsa®, Roclanda® or any current or future product candidates,
including the timing, cost or other aspects of their commercial
launch or commercialization, marketing, manufacturing and supply
management capabilities and strategies in and outside the United
States; the success, timing and cost of our ongoing and anticipated
preclinical studies and clinical trials for Rhopressa® and
Rocklatan®, with respect to regulatory approval outside of the
United States or additional indications, and any current or future
product candidates, including statements regarding the timing of
initiation and completion of the studies and trials; the timing of
and our ability to request, obtain and maintain FDA or other
regulatory authority approval of, or other action with respect to,
as applicable, Rhopressa®, Rocklatan® or any current or future
product candidates; the potential advantages of Rhopressa® and
Rocklatan® or any current or future product candidates; our plans
to pursue development of additional product candidates and
technologies within and beyond ophthalmology; our plans to explore
possible uses of our existing proprietary compounds beyond
glaucoma, including development of our retina program; our ability
to protect our proprietary technology and enforce our intellectual
property rights; and our expectations regarding strategic
operations, including our ability to in-license or acquire
additional ophthalmic products, product candidates or technologies.
We discuss many of the risks associated with our business in
greater detail under the heading “Risk Factors” in the quarterly
and annual reports that we file with the Securities and Exchange
Commission (SEC). Forward-looking statements are not guarantees of
future performance and our actual results of operations, financial
condition and liquidity, and the development of the industry in
which we operate may differ materially from the forward-looking
statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210920005112/en/
Ami Bavishi 908-947-3949; abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024